 ADMA Biologics Inc NASDAQ: ADMA achieved Q3 sales of 20.7 million, 101 YY, beating the consensus of 18.72 million. The increase was favorably impacted by the continued commercial ramp-up of ADMAs intravenous immune globulin IVIG product portfolio and the sale of intermediate fractions. 